Resistance to Targeted Therapies in Multiple Myeloma
Intro -- Aims and Scope -- Objective -- Preface -- Contents -- Series Editor Biography -- About the Series Editor -- Contributors -- About the Editors -- Chapter 1: The Role of Targeted Therapy in Multiple Myeloma -- 1.1 Multiple Myeloma Overview -- 1.2 Historical Treatment of Multiple Myeloma Until Present -- 1.3 Immunomodulatory Imide Drugs -- 1.4 Proteasome Inhibitors -- 1.5 Monoclonal Antibodies -- 1.6 Histone Deacetylase Inhibitors -- 1.7 Bone Targeted Therapy -- 1.8 New Agents on the Horizon -- 1.9 Conclusion -- References -- Chapter 2: Lenalidomide -- 2.1 Introduction -- 2.2 Indications -- 2.3 Efficacy of Lenalidomide -- 2.3.1 Efficacy in Relapsed or Refractory Multiple Myeloma -- 2.3.1.1 Lenalidomide and Dexamethasone -- 2.3.1.2 Bortezomib, Lenalidomide, and Dexamethasone -- 2.3.1.3 Daratumumab, Lenalidomide, and Dexamethasone -- 2.3.1.4 Carfilzomib, Lenalidomide, and Dexamethasone -- 2.3.2 Efficacy in Newly Diagnosed Multiple Myeloma -- 2.3.2.1 Transplant Ineligible Patients -- Lenalidomide and Dexamethasone -- Cyclophosphamide, Lenalidomide, and Dexamethasone -- Bortezomib, Lenalidomide, and Dexamethasone -- 2.3.2.2 Transplant Eligible Patients -- Bortezomib, Lenalidomide, and Dexamethasone -- 2.4 Mechanisms of Action -- 2.4.1 Cereblon Pathway -- 2.4.2 Effect on Cytokines -- 2.4.3 T Cell Activation -- 2.4.4 Effect on Natural Killer Cells -- 2.4.5 Anti-Angiogenic Activity -- 2.4.6 Direct Antitumor Activity -- 2.4.7 Myeloma Microenvironment -- 2.5 Lenalidomide Resistance -- 2.5.1 Potential Mechanisms of Lenalidomide Resistance -- 2.5.1.1 Decreased Cereblon Expression and Downstream Factors -- 2.5.1.2 Increase in c-Myc -- 2.5.2 Management of Lenalidomide-Resistant Disease -- 2.5.2.1 Pomalidomide-Based Regimes -- 2.5.2.2 Proteasome Inhibitor and Daratumumab-Based Regimes -- 2.6 Conclusion -- References -- Chapter 3: Pomalidomide..
Medienart: |
E-Book |
---|
Erscheinungsjahr: |
2021 ©2021 |
---|---|
Erschienen: |
Cham: Springer International Publishing AG ; 2021 ©2021 |
Reihe: |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ling, Silvia Cw [VerfasserIn] |
---|
Links: |
ebookcentral.proquest.com [lizenzpflichtig] |
---|
ISBN: |
---|
Themen: |
Drug resistance in cancer cells |
---|
Anmerkungen: |
Description based on publisher supplied metadata and other sources |
---|
Umfang: |
1 online resource (161 pages) |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
181682853X |
---|
LEADER | 01000cam a22002652 4500 | ||
---|---|---|---|
001 | 181682853X | ||
003 | DE-627 | ||
005 | 20230427035118.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220916s2021 xx |||||o 00| ||eng c | ||
020 | |a 9783030734404 |9 978-3-030-73440-4 | ||
035 | |a (DE-627)181682853X | ||
035 | |a (DE-599)KEP067363075 | ||
035 | |a (EBC)EBC6683053 | ||
035 | |a (EBL)EBL6683053 | ||
035 | |a (EBP)067363075 | ||
040 | |a DE-627 |b ger |c DE-627 |e rda | ||
041 | |a eng | ||
082 | 0 | |a 616.99418 | |
100 | 1 | |a Ling, Silvia Cw |e verfasserin |4 aut | |
245 | 1 | 0 | |a Resistance to Targeted Therapies in Multiple Myeloma |
264 | 1 | |a Cham |b Springer International Publishing AG |c 2021 | |
264 | 4 | |c ©2021 | |
300 | |a 1 online resource (161 pages) | ||
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
490 | 0 | |a Resistance to Targeted Anti-Cancer Therapeutics Ser. |v v.22 | |
500 | |a Description based on publisher supplied metadata and other sources | ||
520 | |a Intro -- Aims and Scope -- Objective -- Preface -- Contents -- Series Editor Biography -- About the Series Editor -- Contributors -- About the Editors -- Chapter 1: The Role of Targeted Therapy in Multiple Myeloma -- 1.1 Multiple Myeloma Overview -- 1.2 Historical Treatment of Multiple Myeloma Until Present -- 1.3 Immunomodulatory Imide Drugs -- 1.4 Proteasome Inhibitors -- 1.5 Monoclonal Antibodies -- 1.6 Histone Deacetylase Inhibitors -- 1.7 Bone Targeted Therapy -- 1.8 New Agents on the Horizon -- 1.9 Conclusion -- References -- Chapter 2: Lenalidomide -- 2.1 Introduction -- 2.2 Indications -- 2.3 Efficacy of Lenalidomide -- 2.3.1 Efficacy in Relapsed or Refractory Multiple Myeloma -- 2.3.1.1 Lenalidomide and Dexamethasone -- 2.3.1.2 Bortezomib, Lenalidomide, and Dexamethasone -- 2.3.1.3 Daratumumab, Lenalidomide, and Dexamethasone -- 2.3.1.4 Carfilzomib, Lenalidomide, and Dexamethasone -- 2.3.2 Efficacy in Newly Diagnosed Multiple Myeloma -- 2.3.2.1 Transplant Ineligible Patients -- Lenalidomide and Dexamethasone -- Cyclophosphamide, Lenalidomide, and Dexamethasone -- Bortezomib, Lenalidomide, and Dexamethasone -- 2.3.2.2 Transplant Eligible Patients -- Bortezomib, Lenalidomide, and Dexamethasone -- 2.4 Mechanisms of Action -- 2.4.1 Cereblon Pathway -- 2.4.2 Effect on Cytokines -- 2.4.3 T Cell Activation -- 2.4.4 Effect on Natural Killer Cells -- 2.4.5 Anti-Angiogenic Activity -- 2.4.6 Direct Antitumor Activity -- 2.4.7 Myeloma Microenvironment -- 2.5 Lenalidomide Resistance -- 2.5.1 Potential Mechanisms of Lenalidomide Resistance -- 2.5.1.1 Decreased Cereblon Expression and Downstream Factors -- 2.5.1.2 Increase in c-Myc -- 2.5.2 Management of Lenalidomide-Resistant Disease -- 2.5.2.1 Pomalidomide-Based Regimes -- 2.5.2.2 Proteasome Inhibitor and Daratumumab-Based Regimes -- 2.6 Conclusion -- References -- Chapter 3: Pomalidomide. | ||
650 | 0 | |a Drug resistance in cancer cells | |
650 | 0 | |a Multiple myeloma-Treatment | |
650 | 4 | |a Electronic books | |
700 | 1 | |a Trieu, Steven |e mitwirkender |4 ctb | |
776 | 1 | |z 9783030734398 | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783030734398 |
856 | 4 | 0 | |u https://ebookcentral.proquest.com/lib/kxp/detail.action?docID=6683053 |m X:EBC |x Aggregator |z lizenzpflichtig |
912 | |a ZDB-30-PQE | ||
912 | |a GBV_ILN_24 | ||
912 | |a ISIL_DE-8 | ||
912 | |a SYSFLAG_1 | ||
912 | |a GBV_KXP | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_206 | ||
912 | |a ISIL_DE-Brg3 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a ISIL_DE-289 | ||
951 | |a BO | ||
953 | |2 045F |a 616.99418 | ||
980 | |2 24 |1 01 |x 0008 |b 418949920X |h olr-ddaebc |k Diesen Titel können Sie über den Zugriffslink zunächst für kurze Zeit nutzen (1 Campuszugriff zur Zeit möglich) und bei weiterem Bedarf nach persönlicher Registrierung auf der nachfolgenden Seite der Zentralbibliothek zur dauerhaften Anschaffung vorschlagen. Wir werden Sie zügig über die Bereitstellung informieren. |y z |z 16-09-22 | ||
980 | |2 206 |1 01 |x 3350 |b 4189637432 |c 00 |f --%%-- |d Online-Ressource |e g |j --%%-- |h OLR-EBL |k If you are a ThHF affiliate and the E-Book is not fully accessible, please send us a purchase or short time loan request. All others: Inter-library loans and guest access on campus premises is not possible. |y zh |z 17-09-22 | ||
980 | |2 2021 |1 01 |x DE-289 |b 4192934345 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |y l01 |z 28-09-22 | ||
981 | |2 24 |1 01 |x 0008 |r https://ebookcentral.proquest.com/lib/christianalbrechts/detail.action?docID=6683053 | ||
981 | |2 206 |1 01 |x 3350 |y Full Text only for ThHf affiliates |r https://thh-friedensau.idm.oclc.org/login?url=http://ebookcentral.proquest.com/lib/thhfriedensau/detail.action?docID=6683053 | ||
981 | |2 2021 |1 01 |x DE-289 |r https://ebookcentral.proquest.com/lib/kiz-uniulm/detail.action?docID=6683053 | ||
995 | |2 24 |1 01 |x 0008 |a olr-ddaebc | ||
995 | |2 206 |1 01 |x 3350 |a OLR-EBL |